Dabigatran first to the filing post for atrial fibrillation use in Japan
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has filed an application in Japan for the approval of the direct thrombin inhibitor Pradaxa (dabigatran etexilate) for the prevention of stroke in atrial fibrillation (AF) patients.